Recent Updates — NRIX
Nurix Therapeutics reported a net income of $549.8 million, or $4.73 per diluted share, for the fiscal quarter ended August 31, 2026, compared to a net loss of $86.4 million in the prior-year period. Revenue surged to $673.1 million from $7.9 million, driven primarily by a $653.2 million license payment from Roche and a $10.0 million milestone from Sanofi. The company ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities. Clinically, Nurix dosed the first patient in its Phase 3 DAYBreak CLL-306 trial for bexobrutideg and advanced NX-1607 into Phase 1b expansion cohorts across four solid tumor indications. The company is a clinical-stage biopharmaceutical firm focused on targeted protein degradation medicines.
Nurix Therapeutics, Inc. issued a press release on July 9, 2026, announcing its financial results for the fiscal quarter ended May 31, 2026. Nurix Therapeutics, Inc. is a biotechnology company focused on developing and commercializing targeted protein degradation therapies.
On June 11, 2026, Nurix Therapeutics announced updated Phase 1a/1b clinical trial data for bexobrutideg (NX-5948), a BTK degrader for relapsed or refractory CLL and SLL. In the Phase 1a population of 47 evaluable patients, the objective response rate (ORR) was 83.0% with a median progression-free survival of 22.1 months. Phase 1b cohorts showed an ORR of 92.9% for BTKi-treated/BCL2i-naïve patients and 84.2% for BTKi-naïve patients. The drug was well tolerated across 142 patients, including 86 at the 600 mg recommended Phase 2 dose, with no dose-limiting toxicities reported. The company operates in the biotechnology industry and develops targeted protein degradation therapies for cancer.
Nurix Therapeutics, Inc. entered into a License and Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. to develop, manufacture, and commercialize bexobrutideg (NX-5948). Roche will provide an upfront cash payment of $700.0 million, and Nurix is eligible for up to $2.3 billion in total potential payments including milestones and royalties.